Attenuating adaptive VEGF-A and IL-8 signaling restores durable tumor control in AR-antagonist-treated prostate cancers by Maxwell, PJ, McKechnie, M, Armstrong, CW, Manley, JM, Ong, CW, Worthington, J, Mills, IG, Longley, DB, Quigley, JP, Zoubedi, A, de Bono, JS, Deryugina, E, LaBonte, MJ, Waugh, DJJ

Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma by Armstrong, CWD, Coulter, JA, Ong, CW, Maxwell, PJ, Walker, S, Butterworth, KT, Lyubomska, O, Berlingeri, S, Gallagher, R, O’Sullivan, JM, Jain, S, Mills, IG, Prise, KM, Bristow, RG, LaBonte, MJ, Waugh, DJJ